IKT: Inhibikase Pharma Growth-Adjusted Market Cap to Net Income

Corporate company logo of Inhibikase Pharma (IKT)

Inhibikase Therapeutics (IKT) is deploying capital toward R&D without current sales, while developing an advanced system to combat Parkinson's disease via kinase inhibitors. The company's P/E to growth ratio reflects valuation dynamics, with the metric holding at 0.00. This chart confirms the macro-resilience of demand for neuromedicine, as scientific research in this field remains independent of economic cycles.

Inhibikase - IKT PEG Multiple (period 07/04/2022 - 11/16/2026)

Analytical breakdowns for inhibikase.com (IKT)

- share price and consensus valuation forecast:
Fundamental company analysis:IKT, Inhibikase
Signature product of Inhibikase Therapeutics

The stability of Inhibikase Therapeutics (IKT) is determined by the efficiency of completing clinical phases and the ability of c-Abl inhibitors to cross the blood-brain barrier. The P/E ratio relative to earnings growth rates, displayed via the PEG fair value filter, compares the market price with revenue dynamics, where a value below one signals that the asset is undervalued relative to its expansion, allowing the investor to identify potential for rapid growth.

Competing companies

Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Xenon Pharmaceuticals (XENE) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio VKTX|Price/Earnings to Growth Ratio Supernus|Price to Earnings Adjusted for Growth Rate catalystpharma.com CPRX|Price/Earnings to Growth Multiple DNLI (Denali Therapeutics Inc.)|HRMY - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Biohaven Ltd. BHVN|AMLX (Amylyx) - Market Cap to Earnings and Growth Ratio|Trevi Therapeutics Inc - PEG Multiple|Growth-Adjusted Payback Ratio PRAX (Praxis Precision Medicines)|AVXL: PEG Multiple|CBLL - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio prothena.com|Price/Earnings to Growth Multiple Alector (ALEC)|Price/Earnings to Growth Multiple ANNX (annexonbio.com)|OMER - Price to Earnings Adjusted for Growth Rate|PEG Multiple NGNE (Neurogene Inc)|PEG Multiple AC Immune S.A. ACIU|VYGR - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio NMRA|SCLX (Scilex Holding Company) - Price/Earnings to Growth Multiple|TVGN (Tevogen Bio Holdings) - Price/Earnings to Growth Ratio|ACOG (Alpha Cognition Corp) - PEG Multiple|Cognition Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple SAVA (Cassava)|Growth-Adjusted Market Cap to Net Income Assertio Therapeutics|Coya Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Multiple|CRVO (CervoMed, Inc.) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Alterity Therapeutics Ltd|Price/Earnings to Growth Ratio Clene Inc.|PepGen Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Price/Earnings to Growth Ratio RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Grace Tx (GRCE)|fireflyneuro.com - PEG Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple Passage Bio Inc. (PASG)|Price/Earnings to Growth Ratio bionomics.com.au NEUP|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple